Combination treatment with a LSD1 inhibitor is advantageous as both the bulk tumour cell population and the mesenchymal, stem-like, resistance signature are significantly abrogated along with a reduction in CAF signature and increased M1 macrophage and innate immune cell infiltration potentially supporting the role of LSD1 in reducing recurrence. The gene discussed is KDM1A; the disease is neoplasm.